Atossa Therapeutics (ATOS) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ATOS Atossa Therapeutics

Watchlist

0.9394
+0.0005+0.05%

Trading Jan 24 15:16 ET

118.18MMarket Cap-4.47P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Atossa Therapeutics Says Z-Endoxifen To Enter Registrational Clinical Trials In 2025; Updates On Progress Expected Q1; Global Business Development Efforts Amplified; Industry Partnerships Deepened; Financial Strength For Long-Term Growth Emphasized
BenzingaJan 23 08:22 ET
Atossa Therapeutics Issues Letter to Shareholders
TipRanksJan 23 08:20 ET
Express News | Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025
ReutersJan 23 08:15 ET
Atossa Therapeutics Applauds U.S. Surgeon General's Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer
Atossa TherapeuticsJan 6 00:00 ET
TCMD Stock Rises 20% in Three Months: Should You Buy, Hold or Sell?
Zacks Dec 31, 2024 07:35 ET
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $7
Moomoo NewsDec 12, 2024 12:31 ET · Ratings

Comments

Jaguar8

Dec 12, 2024 07:17

NEWS

$Atossa Therapeutics (ATOS.US)$
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
Atossa Therapeutics (NASDAQ: ATOS)has announced groundbreaking research findings on compounds that work synergistically with (Z)-endoxifen for breast cancer treatment. The discovery, presented at the 2024 San Antonio Breast Cancer Symposium, utilized both insilico and chemic...

Jaguar8

Dec 11, 2024 07:18

NEWS

$Atossa Therapeutics (ATOS.US)$
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
Wednesday, 11th December at 8:15 am
1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer
Data to be Presented in a Poster Spotlight Session During the 2024 San Antonio Breast Cancer Symposium
SEATTLE, Dec. 11, 202...

Jaguar8

Dec 10, 2024 08:05

NEWS

$Atossa Therapeutics (ATOS.US)$
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
Tuesday, 10th December at 9:05 am
SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today ann...